Innovation

Representative Blake Moore (R-Utah, District 1) speaks during a House Committee on Ways and Means hearing held at ARUP Laboratories. Pictured from left to right are Celeste Maloy (R-Utah, District 2), Burgess Owens (R-Utah, District 4), Moore, Jason Smith (R-Missouri, District 8), and Brad Wenstrup, MD (R-Ohio, District 2).

Rep. Blake Moore (R-UT) and other members of the Ways and Means Committee’s Health Subcommittee will participate in a field hearing on July 12 at ARUP Laboratories.

Andy Theurer, ARUP CEO, speaks to a crowd gathered to celebrate ARUP’s 40th anniversary. Others on stage include, from left to right, Tracy I. George, MD, ARUP chief scientific officer and president of the Innovation Business Unit, Julio C. Delgado, MD, MS, ARUP executive vice president and vice chair and chief of Clinical Pathology at the University of Utah, and Carl R. Kjeldsberg, MD, an ARUP founder and former CEO.

Presentations and posters will cover topics such as mycobacterial infections, increasing rates of macrolide drug resistance, the state of parasitology following the COVID-19 pandemic, and more.

Erica Clyde speaks with attendees at BioHive Live.

An expert in TAR DNA-binding protein of 43 kDa (TDP-43), neuropathologist Qinwen Mao, MD, PhD, subspecialty director of Neuropathology at ARUP, is working to identify biomarkers that predict the presence of TDP-43 pathology to contribute to the diagnosis of frontotemporal lobar degeneration (FTLD) and Alzheimer’s disease.

ARUP survey shows “profound” concern within the lab community about the FDA’s proposed rule.

Tracy George, MD (third from right), ARUP’s chief scientific officer and president of the Innovation Business Unit, holds a zebra, the mascot for patients with rare diseases, and poses for a photo with participants in Salt Lake City’s Rare Disease Day event. Pictured, from left to right, are Tanner Withers, parent of a child with a rare disease, Troy Evans, undiagnosed patient with a rare disease, Rebecca Yates, parent of a child with a rare disease, Matt Pearl, patient with a rare disease, Ava and Lucy Szajunk, undiagnosed patients with rare diseases, George, Chris Gibson, PhD, CEO of Recursion, and Kelvyn Cullimore, president and CEO of BioUtah.

MetaCensus is built to support the exchange and review of data by various stakeholders and performs multicriteria decision analysis (MCDA) to assess and account for varying perspectives, counterpoints, and biases.

ARUP medical directors and scientists, including (from left to right) Sherin Shaaban, MD, PhD, FACMG; Yuan Ji, PhD, MBA, DABCP, FACMG; and Hunter Best, PhD, FACMG, along with others, will present their latest research and share insights for current and future geneticists at the Annual Clinical Genetics Meeting in March.

ARUP medical directors and scientists advanced laboratory medicine and improved patient care with publication of more than 130 peer-reviewed articles in fiscal year 2023.